Comerica Bank’s Spyre Therapeutics SYRE Stock Holding History

Comerica Bank’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$164	Hold	5	–	–	﹤0.01%	3676
2025 Q3	$84	Buy	+5	New	+$82	﹤0.01%	3691

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Comerica Bank's SYRE Position: Q4 2025 in Review

Comerica Bank held its Spyre Therapeutics (SYRE) position steady in Q4 2025 at 5 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #3676.

Comerica Bank first reported a position in SYRE in Q3 2025 and has held it in 2 quarters since. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

Comerica Bank held 5 shares of Spyre Therapeutics worth $164 as of Q4 2025.
Comerica Bank left its Spyre Therapeutics share count unchanged in Q4 2025.
Spyre Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3676 holding.
Comerica Bank first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 2 quarters since.
153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.